Neurotop Retard (Carbamazepine)

Carbamazepine blocks voltage‑gated sodium channels on neuronal membranes, preventing rapid sodium influx during depolarisation. This stabilises hyper‑excited neurons, reduces repetitive firing, and limits the spread of abnormal electrical activity that underlies seizures and neuropathic pain.

The specific dose of Neurotop Retard is determined by the prescribing clinician based on the patient’s age, weight, indication, renal and hepatic function, and response to therapy. Dosage adjustments are made individually and should follow the prescriber’s written instructions.

Carbamazepine is classified as pregnancy category D, indicating evidence of risk to the fetus. It should only be used when the potential benefit justifies the risk. Carbamazepine is excreted in breast milk; breastfeeding decisions should be made after consulting a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with alternatives such as phenytoin or valproate, carbamazepine offers a distinct sodium‑channel blocking profile and is particularly effective for focal seizures and trigeminal neuralgia. Its side‑effect spectrum differs, with a higher incidence of hyponatremia but lower risk of weight gain than some mood stabilisers.

Neurotop Retard should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, heat and direct sunlight, and ensure the packaging remains tightly closed until use.

Neurotop Retard is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed, unless the prescriber provides specific instructions for a particular formulation.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, blood dyscrasias like agranulocytosis or aplastic anemia, and hepatic failure. Patients should be instructed to seek immediate medical attention if they develop rash, fever, sore throat, jaundice, or unexplained bruising.

Neurotop Retard is contraindicated in individuals with known hypersensitivity to carbamazepine or other dibenzazepine derivatives, in patients with a history of bone marrow depression, and in those with certain cardiac conduction disorders unless closely monitored. Pregnant women should only use it when clearly indicated.